Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)

Free Radical Research

Volumn 31, Issue 3, 1999, Pages 171-179

  Reljanovic, M ^a   Reichel, G ^b   Rett, K ^c   Lobisch, M ^d   Schuette, K ^d   Moller W ^d   Tritschler, H J ^d   Mehnert, H ^e  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Paracelsus Klinik   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ASTA MEDICA AG   (Germany)

^e INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

Author keywords

lipoic acid; Antioxidants; Diabetic polyneuropathy; Thioctic acid; Treatment

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; THIOCTIC ACID; TROMETAMOL;

ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ELECTROPHYSIOLOGY; FEMALE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LATENT PERIOD; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR NERVE; MULTICENTER STUDY; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSORY NERVE; SKIN ULCER; SLEEP DISORDER; STATISTICAL ANALYSIS; SURAL NERVE; TIBIAL NERVE; VERTIGO; VISUAL DISORDER;

ACTION POTENTIALS; ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS; PROSPECTIVE STUDIES; SURAL NERVE; THIOCTIC ACID; TIBIAL NERVE;

EID: 0032881613     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/10715769900300721     Document Type: Article

References (47)

1. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329: 977-986.
2. UK-Prospective Diabetes Study (UKPDS)-group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared to conventional treatment and risk of complications in patients with type II diabetes. (UKPDS 33). Lancet, 352; 837-853.
3. D. Ziegler, M. Hanefeld, K.J. Ruhnau, H.P. Meißner, M. Lobisch, K. Schütte, F.A. Gries and The ALADIN Study Group (1995) Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38: 1425-1433.
4. 1 bei der diabetischen Neuropathie. Diabetes und Stoftwechsel, 2: 443-448.
5. M. Kihara, J.D. Schmelzer and J.F. Poduslo (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proceedings of the National Academy of Sciences, 88: 6107-6111.
6. E.A. Masson and A.J.M. Boulton (1990) Aldose reductase inhibitors in the treatment of DNP. A review of the rationale and clinical evidence. Drugs, 39: 190-202.
7. D. Giugliano, R. Marfella, A. Quatraro, N. DeRosa, T. Salvatore, D. Cozzolino, A. Ceriello and R. Torella (1993) Tolrestat for mild diabetic neuropathy: A 52 week, randomized, placebo-controlled trial. Annals of Internal Medicine, 118: 7-11.
8. P.K. Thomas (1994) Growth factors and diabetic neuropathy. Diabetic Medicine, 11: 732-739.
9. R. Hellweg and H.D. Hartung (1990) Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. Journal of Neuroscience Research, 26: 258-267.
10. N.E. Cameron and M.A. Cotter (1994) The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metabolism Reviews, 10: 189-224.
11. G.A. Jamal (1994) The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetic Medicine, 11: 145-149.
12. A. Quatraro, P. Roca, C. Donella, R. Acampora, R. Marfella and D. Giugliano (1995) Acetyl-L-Carnetine for symptomatic diabetic neuropathy. Diabetologia, 38: 123.
13. P. Low and K.K. Nickander (1991) Oxygen free radicals effects in sciatic nerve in experimental diabetes. Diabetes, 40: 873-877.
14. K.K. Nickander, J.D. Schmelzer, D.A. Rohwer and P.A. Low (1994) Effects of α-tocopherol deficiency on indices of oxidative stress in normal and diabetic peripheral nerve. Journal of Neurological Sciences, 126: 6-14.
15. N.E. Cameron, M.A. Cotter, V. Archibald, K.C. Dines and E.K. Maxfield (1994) Antioxidant and pro-oxidant effects on nerve conduction velocity, endoneuronal blood flow and oxygen tension in non-diabetic and streptozotocin diabetic rats. Diabetologia, 37: 449-459.
16. B.C. Scott, O.I. Aruoma, P.J. Evans, C. O'Neill, A. van der Vliet, C.E. Cross, H. Tritschler and B. Halliwell (1994) Lipoic and dihydrolipoic acid as antioxidants. A critical evaluation. Free Radical Research Communications, 20: 119-133.
17. L. Packer, E.H. Witt and H.J. Tritschler (1996) Alpha-lipoic acid: The metabolic antioxidant. Free Radicals in Biology and Medicine, 20: 625-626.
18. D. Han, G. Handelman, L. Marcocci, C.K. Sen, S. Roy, H. Kobuchi, H.J. Tritschler, L. Flohé and L. Packer (1997) Lipoic acid increases de novo, synthesis of cellular glutathione by improving cystine utilzation. Journal of Biological Factors, 9: 1-18.
19. K.K. Nickander, B.R. McPhee, P.A. Low and H.J. Tritschler (1996) Alpha-lipoic acid: Antioxidant potency against lipid peroxidation of neural tissues in vitro, and implications for DNP. Free Radicals in Biology and Medicine, 21: 631-639.
20. M. Nagamatsu, K.K. Nickander, J.D. Schmelzer, A. Raya, A. Wittrock, H. Tritschler and P.A. Low (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care, 18: 1160-1166.
21. P.S. van Dam, B.S. van Asbeck, A. Bravenboer, J.F.L.M. van Oirschot, W.H. Gispen and J.J.M. Marx (1995) Effects of α-lipoic acid and glutathione on systemic and aciatic nerve antioxidant levels in expertimental diabetes. Elsevier Science B. V.: 223-228.
22. K. Murase, A. Hattori, M. Kohno and K. Hayashi (1993) Stimulation of nerve growth factor synthesis secretion in mouse astroglial cells by coenzymes. Biochemistry and Molecular Biology International, 30: 615-621.
23. N.E. Garrett, M. Malcangio, M. Dewhurst and D.R. Tomlinson (1997) α-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neuroscience Letters, 222: 191-194.
24. W. Dimpfel, M. Spüler, F.K. Piernau and H. Ulrich (1990) TA induces dose-dependent sprouting of neurites in cultured rat neuroblastoma cells. Developments in Pharmacology and Therapy, 14: 193-199.
25. D. Ziegler, H. Schatz, F. Conrad, F.A. Gries, H. Ulrich, G. Reichel and The DEKAN Study Group (1993) Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter Trial (DEKAN-Study). Diabetes Care, 20: 369-373.
26. M. Storr and M. Bluthardt (1993) Atlas der klinischen Elektrophysiologie und Neurographie. W. Kahlhammer.
27. M.J. Young, A.J.M. Boulton, A.F. Maclead, D.D.R. Williams and P.H. Sonksen (1993) A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologica, 36: 150-154.
28. P.J. Dyck, and P.C. O'Brien (1989) Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic polyneuropathy. Diabetes Care, 12: 649-652.
29. The Peripheral Nerve Society (1995) Diabetic polyneuropathy in controlled clinical trials: consensus report of the peripheral nerve society. Annals of Neurology, 38: 478-482.
30. J.W. Baynes (1991) Role of oxidative stress in development of complications in diabetes. Diabetes, 40: 405-412.
31. N.E. Cameron, and M.A. Cotter (1997) Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes, 46 (Suppl 2): 31-37.
32. P.A. Low, K.K. Nickander and H.J. Tritschler (1997) The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes, 46 (Suppl 2): 38-42.
33. M. Kihara and P.A. Low (1995) Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Experimental Neurology, 132: 180-185.
34. D. Strödter, E. Lehmann, U. Lehmann, H.J. Tritschle, R.G. Bretzel and K. Federlin (1995) The influence of TA on metabolism and function of the diabetic heart. Diabetes Research and Clinical Practice, 29: 19-26.
35. P.A. Low, J.K. Yao, Y. Kishi, H.J. Tritschler, J.D. Schmelzer, P.J. Zollmann and K.K. Nickander (1997) Peripheral nerve energy metabolism in experimental diabetes. Neuroscience Research Communications, 21: 49-56.
36. M.A. Cotter, A. Keegan and N.E. Cameron (1998) Defective corpus cavernosum function in diabetic rats: effects of antioxidants. Diabetologia, 41 (Suppl 1): A 51.
37. A. Jack, M.A. Cotter and N.E. Cameron (1998) Antioxidant treatment effects on defective endothelium-derived hyperpolarizing factor and relaxation in the mesenteric vasculature of diabetic rats. Diabetes, 47 (Suppl 1): A54.
38. I. Obrosova, X. Cao, D.A. Greene and M.J. Stevens (1998) Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-α-lipoic acid. Diabetologia, 41: 1442-1450.
39. D.A. Greene, X. Cao, C. van Huysen and I.G. Obrosova (1998) Effects of DL-α-lipoic acid (LA) on diabetic nerve function, bioenergetics, and antioxidative defense. Diabetes, 47 (Suppl 1): A136.
40. N.E. Cameron, M.A. Cotter, D.H. Horrobin and H.J. Tritschler (1998) Effects of α-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia, 41: 390-399.
41. L. Hounsom, D.F. Horrobin, H. Tritschler, R. Corder and D.R. Tomlinson (1998) A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia, 41: 839-843.
42. A. Bierhaus, S. Chevion, M. Chevion, M. Hofmann, P. Quehenberger, T. Illmer, T. Luther, E. Berentshtein, H. Tritschler, M. Mueller, P. Wahl, R. Ziegler and P.P. Nawroth (1997) Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes, 46: 1481-1490.
43. M.A. Hofmann, S. Schiekofer, B. Isermann, M. Kanitz, M. Henkels, M. Joswig, A. Treusch, M. Morcos, T. Weiss, V. Borcea, A.K.M. Abdel Khalek, J. Amiral, H. Tritschler, E. Ritz, P. Wahl, R. Ziegler, A. Bierhaus and P.P. Nawroth (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia, 42: 222-232.
44. S. Jacob, E.J. Henriksen, H.J. Tritschler, H.J. Augustin and G.J. Dietze (1996) Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Experimental and Clinical Endocrinology and Diabetes, 104: 284-288.
45. S. Jacob, E.J. Henriksen, H.J. Tritschler, D.E. Clancy, I. Simon, A. Schiemann, H. Ulrich, W.I. Jung, G.J. Dietze and H.J. Augustin (1995) α-lipoic acid enhances glucose-disposal in patients with type II diabetes. Arzneimittel-Forschung/Drug Research, 45: 872-874.
46. T. Konrad, P. Vicini, K. Kusterer, A. Höflich, A. Assadkhani, H.J. Böhles, A. Sewell, H.J. Tritschler, C. Cobelli and K.H. Usadel (1999) α-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with Type 2 diabetes. Diabetes Care, 22: 280-287.
47. V. Borcea, J. Nourooz-Zadeh, S.P. Wolff, M. Zumbach, M. Hofmann, H. Ulrich, P. Wahl, R. Ziegler, H. Tritschler, B. Halliwell and P.P. Nawroth (1999) α-Lipoic acid decreases oxidative stress measures in patients with diabetes mellitus. Free Radicals in Biology and Medicine, (in press).